Uniqure N.V (QURE) | Stock Overview & Key Data
Uniqure N.V Performance Comparison
Stock Range
Today's Range
Low: $54.11
High: $56.99
on October 2, 2025
52 Week Range
Low: $4.45
High: $60.70
on October 3, 2024
on September 30, 2025
All-Time High: $82.49 on June 17, 2019
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.0B
EPS
-4.18
P/E Ratio (TTM)
-11.18
Forward P/E
-19.08
P/B Ratio
-752.91
PEG Ratio
0.28
Div. Yield
N/A
ROE
-427.47%
Beta
0.134
Debt to Equity
-130.39
Financial Highlights
Profitability
Gross Margin
87.53%
Operating Margin
-790.78%
Profit Margin
32.42%
Returns and Earnings
Return on Assets (TTM)
-15.39%
Return on Equity (TTM)
-427.47%
EBITDA
$-146.4M
Net Income (TTM)
$-199.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.29
Quarterly Revenue Growth (YoY)
-52.70%
Quarterly Earnings Growth (YoY)
-52.71%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Uniqure N.V QURE | 3.02B Mid-cap | 3.51% | 220.40% | 281.65% | 413.18% | 201.94% | 864.60% | 182.53% | 48.22% |
| Vertex VRTX | 100.41B Large-cap | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% | -10.20% | 38.49% | 51.45% |
| Alnylam ALNY | 60.43B Large-cap | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% | 72.02% | 135.43% | 213.60% |
| Madrigal MDGL | 9.88B Mid-cap | 6.30% | 3.10% | 49.81% | 34.38% | 43.30% | 115.75% | 499.28% | 247.00% |
| Moderna MRNA | 9.86B Mid-cap | 15.28% | 17.28% | -6.31% | 2.34% | -32.45% | -52.87% | -76.22% | -61.14% |
| Corcept Therapeutics CORT | 8.96B Mid-cap | 3.32% | 19.75% | 19.82% | 1.99% | 71.06% | 88.16% | 222.81% | 365.83% |
Ownership & Short Interest
Insider Ownership
6.07%
Institutional Ownership
96.94%
Shares Short
8M
Short Ratio
8.01
Short % of Shares Outstanding
15.28%
Average 10-Day Volume
12M
Average 90-Day Volume
5M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is QURE's 52-week high and low?
- In the last 52 weeks, Uniqure N.V reached a high of $60.70 (on September 30, 2025) and a low of $4.45 (on October 3, 2024).
- What is the market cap and P/E ratio for QURE?
- Curious about Uniqure N.V's size and valuation? Its market capitalization stands at 3.02B. When it comes to valuation, the P/E ratio (trailing twelve months) is -11.18, and the forward P/E (looking ahead) is -19.08.
- Does QURE pay dividends? If so, what's the yield?
- As for dividends, Uniqure N.V isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Uniqure N.V's main competitors or similar companies to consider before investing?
When looking at Uniqure N.V, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.41B Healthcare Biotechnology -10.20% 38.49% Alnylam
ALNY60.43B Healthcare Biotechnology 72.02% 135.43% Madrigal
MDGL9.88B Healthcare Biotechnology 115.75% 499.28% Moderna
MRNA9.86B Healthcare Biotechnology -52.87% -76.22% Corcept Therapeutics
CORT8.96B Healthcare Biotechnology 88.16% 222.81% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Uniqure N.V.? (e.g., ROE, Debt/Equity)
- To get a sense of Uniqure N.V's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -427.47%, the Debt to Equity ratio from the most recent quarter is -130.39, and its Gross Profit Margin stands at 87.53%.
- What is the recent revenue and earnings growth for QURE?
- Looking at Uniqure N.V's growth, its revenue over the trailing twelve months (TTM) was $14M. Compared to the same quarter last year (YoY), quarterly revenue grew by -52.70%, and quarterly earnings saw a YoY growth of -52.71%.
- How much of QURE stock is held by insiders and institutions?
- Wondering who owns Uniqure N.V stock? Company insiders (like executives and directors) hold about 6.07% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.94%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.